Clinical trial
AMG 531 in Patients With Advanced Malignancy Receiving Treatment With…
NCT00147225 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00147225 |
|---|---|
| Title | AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin |
| Official title | Phase I/II Study of AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Solid Tumors, Advanced Cancer |
| Intervention type | Drug |
| Interventions | AMG 531, Carboplatin, Adriamycin, Ifosfamide |
| Enrollment | 55 |
| Start date | Aug 1, 2005 |
| Primary completion | Mar 1, 2013 |
| Completion | Mar 1, 2013 |
| First posted | Sep 7, 2005 |
| Last update posted | May 8, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: